Ariad Reaches Agreement With FDA for Phase III Cancer Drug Trial
Posted on: Tuesday, 11 September 2007, 12:00 CDT
Ariad Pharmaceuticals has reached agreement on a special protocol assessment with the FDA for its global Phase III trial of oral deforolimus in patients with metastatic sarcomas.
Based on the assessment, progression-free survival (PFS) will be the primary endpoint of the Phase III trial and overall survival will be a secondary endpoint. The company expects to begin patient enrollment in the trial later in September.
The special protocol assessment (SPA) is a written agreement between the trial's sponsor and the FDA regarding the design, endpoints, and planned conduct and analysis of a trial to be used in support of regulatory approval.
The European Medicines Agency (EMEA) has provided protocol advice consistent with that of the FDA regarding the Phase III trial design as part of its protocol assistance program. Ariad and Merck & Co. have a global collaboration to jointly develop and commercialize deforolimus for use in cancer.
Ariad and Merck plan to conduct a Phase III trial of oral deforolimus in patients with metastatic soft tissue and bone sarcomas following a favorable response to chemotherapy - a period when continued treatment with traditional chemotherapeutic agents has not been established to provide additional clinical benefit.
This double-blind trial is designed to evaluate approximately 650 patients who will be randomized (1:1) to oral deforolimus or placebo at approximately 125 sites. Complete patient enrollment and the second interim analysis are expected to take place within approximately two years of the first patient being enrolled.
Pierre Dodion, senior vice president of oncology at Araid, said: "FDA agreement on our overall Phase III trial design, patient population and endpoints, as well as our newly established partnership with Merck represent important achievements for the global development of deforolimus."
Source: Datamonitor
Related Articles
- Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia
- Sub-Analysis of Phase III Suggests Long-Term Therapy May Improve Physical and Social Functioning In CIDP Patients
- Apthera Files Clinical Protocol for Phase III Cancer Drug
- Apthera Files a Phase III Special Protocol Assessment With FDA for NeuVax(TM) in Early-Stage Breast Cancer Patients
- Cogentus to Launch Phase III Program of Novel Combination Product Designed to Reduce Bleeding Side Effect of Antiplatelet Therapy
- Merck & Co.'s Cholesterol Drug Reaches Phase III Trial Goals
- Isolagen and FDA Agree Phase III Trial Design
- Intracel and FDA Agree on Pivotal Phase III Clinical Protocol for Colon Cancer Vaccine
- InterMune Completes Enrollment of the Phase III INSPIRE Trial
- Indevus Announces Positive Phase II Results for Sanctura XR; Trial Supports Phase III Initiation in Overactive Bladder
 |
 |
User Comments (0)
RSS Feeds